文献速递细菌感染、耐药与抗菌药物

莫诺霉素对多重耐药淋病奈瑟菌具有广泛活性,并可清除小鼠阴道感染模型中的感染

Moenomycin is broadly active against multidrug-resistant Neisseria gonorrhoeae and clears an infection from a murine vaginal tract infection model.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究采用琼脂稀释法检测莫诺霉素对575株临床分离株(含FC428克隆相关株)的体外活性,并在小鼠阴道淋球菌感染模型中评估体内活性。结果显示莫诺霉素MIC范围为0.004-0.06 mg/L,MIC50为0.016 mg/L,MIC90为0.03 mg/L;与头孢曲松敏感性相关性差(R=0.13),联合药敏试验FICI均为无关;时间杀菌试验显示4小时暴露后杀菌超过10^4倍;肌肉注射10 mg/kg连续2天可在第二剂后1-3天内清除小鼠阴道感染,显著快于赋形剂对照组(P<0.0001)。

要点

  • 莫诺霉素对575株淋球菌临床分离株MIC50为0.016 mg/L,MIC90为0.03 mg/L。
  • 莫诺霉素与头孢曲松敏感性相关性差(R=0.13),交叉耐药可能性小。
  • 小鼠模型中10 mg/kg连续2天肌肉注射可清除感染,快于对照(P<0.0001)。

核心结论

  • 莫诺霉素对淋病奈瑟菌具有强效体外和体内抗菌活性,值得进一步探索作为替代疗法。

研究设计与样本

  • 体外抗菌活性采用琼脂稀释法检测575株临床分离株,包括FC428克隆相关株。
  • 体内活性采用小鼠阴道淋球菌感染模型评估。
  • 检测指标包括MIC范围、MIC50、MIC90、与头孢曲松敏感性相关性、FICI、时间杀菌试验及体内清除时间。

主要发现

  • 莫诺霉素对菌株库的MIC范围为0.004-0.06 mg/L,MIC50为0.016 mg/L,MIC90为0.03 mg/L。
  • 莫诺霉素与头孢曲松敏感性水平相关性差(R=0.13),所有测试菌株的FICI均为无关,提示两者之间不易产生交叉耐药。
  • 时间杀菌试验显示莫诺霉素为杀菌剂,4小时暴露后杀菌超过10^4倍。
  • 肌肉注射10 mg/kg连续2天可在第二剂后1-3天内清除小鼠阴道淋球菌感染,显著快于赋形剂对照组(P<0.0001)。

关键数值与推荐

  • 莫诺霉素对575株淋球菌临床分离株的MIC范围为0.004-0.06 mg/L,MIC50为0.016 mg/L,MIC90为0.03 mg/L。
  • 莫诺霉素与头孢曲松敏感性相关性R=0.13,FICI均为无关。
  • 时间杀菌试验中4小时暴露后杀菌超过10^4倍。
  • 小鼠模型中肌肉注射10 mg/kg连续2天,感染在第二剂后1-3天内清除,与赋形剂对照组相比P<0.0001。

临床怎么用

  • 原文结论认为莫诺霉素值得进一步探索作为替代疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ceftriaxone therapy for gonorrhoea has become under increasing pressure due to waning susceptibility levels and emergence of high-level resistant strains such as the FC428 clone. Moenomycin was recently identified to display potent anti-gonococcal activity against some reference strains. Therefore, the aim of this study was to investigate moenomycin in vitro and in vivo antimicrobial activity. METHODS: Moenomycin in vitro antimicrobial activity was investigated against 575 clinical isolates, including strains associated with the FC428 clone, using the agar dilution method. Moenomycin in vivo activity was investigated in a mouse vaginal tract gonococcal infection model. RESULTS: The moenomycin MIC range for the strain collection was 0.004-0.06 mg/L, with a MIC50 of 0.016 mg/L and a MIC90 of 0.03 mg/L. The correlation between moenomycin and ceftriaxone susceptibility levels was poor (R = 0.13), while the fractional inhibitory concentration index (FICI) resulted in indifference for all tested strains. Therefore, development of cross-resistance between moenomycin and ceftriaxone is unlikely for N. gonorrhoeae. Determination of the moenomycin mode of activity against N. gonorrhoeae by time-kill assays showed that moenomycin is bactericidal, with over 104-fold inactivation observed after 4 h exposure. Finally, an intramuscular moenomycin dose of 10 mg/kg given on 2 consecutive days was able to clear a gonococcal infection in a mouse vaginal tract infection model within 1-3 days after the second dose, which was significantly faster than for mice treated with the vehicle control (P < 0.0001). CONCLUSIONS: Moenomycin displays potent in vitro and in vivo antimicrobial activity against N. gonorrhoeae, warranting further exploration as alternative therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Yang F, Gao S, Yan J, et al. Moenomycin is broadly active against multidrug-resistant Neisseria gonorrhoeae and clears an infection from a murine vaginal tract infection model. J Antimicrob Chemother. 2022. PMID: 35762496. doi:10.1093/jac/dkac202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。